OLEMA PHARMACEUTICALS INC reports a Return on Equity (ROE) of -38.53%.

What is OLMA's dividend yield?

OLEMA PHARMACEUTICALS INC offers a dividend yield of 0.00%.

What is OLMA's Deepscope Quality Score?

Deepscope rates OLMA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy OLMA?

Deepscope's AI Timing Score for OLMA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does OLMA belong to?

OLEMA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.

OLMA (NASDAQ) Stock Analysis | OLEMA PHARMACEUTICALS INC

Stock Check Daily update data at 9:30 AM
(Price: 2026-06-05 | FS: 2026-03-31)

OLMA

OLEMA PHARMACEUTICALS INC

US:NASDAQ STOCK Healthcare >> Biotechnology News 56

USD 10.31

-0.37 (-3.46%) Day Change

Watchlist Portfolio Compare Chart

0.01

D/E

-38.5%

ROE

-34.9%

ROA

0.00%

Div Yield

OLEMA PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 10.31 Price -0.37 (-3.46%) Day Change	NEWS SCORE: 56

OLMA, the overall quality is not good ( Quality = 15) and the timing to buy is ...(Sign In to See)...

Loading chart...

15 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Lorem ipsum dolor sit amet

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

39%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	56
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	10.31
PBV / Sector	1.94 / 4.63
Earning Per Share	-2.05

PE / Sector	N/A / 17.43
PEG or PE/Growth / Sector	N/A / 0.53
Average 1M Daily Value	16.57 M GREAT
Average 1W Daily Value	18.16 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

45%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

37%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	N/A / 449.48
NPM Average (%) / Sector	N/A / -1,506.49
NPM Change Average (%) / Sector	N/A / 4,940.99
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-34.89 / 30.58
ROA Average (%) / Sector	-35.31 / -347.17
ROA Change Average (%) / Sector	-5.93 / 5,125.52
ROE (%) / Sector	-38.53 / -3.58
ROE Average (%) / Sector	-38.83 / 40.65
ROE Change Average (%) / Sector	-5.70 / 2,109.80
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.05
Dividend Average (%) / Sector	N/A / 16.49
Dividend Change Average (%) / Sector	N/A / 4.17

Registration Details

Analyze Date	2026-06-06 09:09:05
Symbol	OLMA
Name	OLEMA PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	87.35 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	932.87 / 8,857.28

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 780 Brannan Street, San Francisco, CA, United States, 94103

Phone: 415 651 3316

Website: https://olema.com

Employees: 137

Sector: Healthcare >> Biotechnology

Description: Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.